Search Results 2051-2060 of 20154 for Receptor

  1. Publications - Kevin D. Chodnicki, M.D. - Mayo Clinic

    Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy. Semin Ophthalmol. 2021 May 19; 36 (4):329-334 Epub 2021 Mar 10. View PubMed; Tanke LB ...

  2. A Study to Evaluate the Safety of Lixivaptan in Subjects Previously Treated with Tolvaptan for Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    Appropriate control of hypertension including an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (unless not considered appropriate ...

  3. Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy - Mayo Clinic

    ... receptor (AR) inhibitor agents previously for prostate cancer should have received the last dose of the previously administered systemic therapy ≥ 12 ...

  4. Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients with Early-Stage Breast Cancer that was Removed by Surgery - Mayo Clinic

    Non-hormone-sensitive breast cancer (estrogen and progesterone receptor negative (ER- and PR-) or; Grade III histology or; Oncotype recurrence score > 25 or.

  5. A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer - Mayo Clinic

    Has received prior taxane or anti-insulin growth factor receptor (IGFR) therapy; Must not have any of the following conditions. Poorly controlled diabetes ...

  6. A Study Using Docetaxel with or without MLN1117 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Mayo Clinic

    Has taken histamine-H2 receptor antagonists and/or neutralizing antacids within 24 hours before the first administration of study drug; Has taken proton pump ...

  7. MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment - Mayo Clinic

    OR Negative by Dual-probe ISH defined as a HER2/CEP17 ratio <2.0 with an average HER2 copy number <4.0 signals/cell. Cohort 1: hormone receptor positive ...

  8. A Study to Evaluate Variations in Episcleral Venous Pressure - Mayo Clinic

    ... receptor blockers). Subjects with a history or presence of any systemic condition (e.g., heart failure or kidney disease) for which drinking the water ...

  9. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...

  10. Neurosurgery - Clinical trials

    ... receptor (ER and PR) all negative], HER2 positive whatever the ER/PR status,, and HER2 negative/ER positive), (5) advanced, unresectable colorectal cancer ...